Several early studies suggest that sub-hallucinogenic doses of psilocybin, taken on intermittent schedules, may support mood and reduce depressive symptoms. One systematic study found benefits in people without a current mood disorder diagnosis. The evidence is preliminary, and no findings should be read as medical guidance. Key takeaways Microdoses are very small: roughly one-tenth to […]
In a small pilot trial of 10 adults with migraine, participants reported fewer attacks and less severe pain during the two weeks following low-dose oral psilocybin. A separate large survey also found an association between lifetime psychedelic use and lower rates of frequent bad headaches, though neither study proves psilocybin prevents migraines. Key takeaways Reduced […]
Psilocybin, the active compound in certain fungi, primarily acts on serotonin receptors in the brain. Research suggests it disrupts ordinary patterns of neural communication and may increase connectivity between brain regions that do not typically talk to one another, according to a Psychology Today overview published in January 2025. Key takeaways Serotonin receptor activity: Research […]